Clinical Trials · NCT03141671
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 345
- Start date
- Nov 2017
- Locations
- 8 sites, United States
- Primary endpoint
- PSA Progression Free Survival